޲Ʊ

޲Ʊ Sets Up a Subsidiary in Austria

޲Ʊ., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “޲Ʊ”) announced today that the Company had established its new subsidiary, ޲Ʊ GesmbH (Location: Vienna, General Manager: Georg Wager, “޲Ʊ Austria”) in Austria. ޲Ʊ Austria is a subsidiary wholly-owned by ޲Ʊ Europe Limited (Headquarters: Hatfield, UK, Chairman & CEO: Yutaka Tsuchiya, “޲Ʊ Europe”), the European subsidiary of ޲Ʊ.

޲Ʊ entered into the Austrian market in 2005 setting up a branch of its German subsidiary ޲Ʊ GmbH (Location: Frankfurt, Managing Director: Andreas Wiegand). The Austrian branch has been marketing Zonegran® and Inovelon® for the treatment of epilepsy, Neurobloc® for cervical dystonia, Prialt® for severe chronic pain, and also collaborating in the promotion of Aricept® for Alzheimer's Disease. It has also served as a support centre for marketing, medical and regulatory affairs for the business operations in Central and Eastern Europe.

With the establishment of a subsidiary in Austria, a subsidiary wholly-owned by ޲Ʊ Europe, ޲Ʊ will strengthen its business operations in Austria and Central and Eastern European countries in preparation for future possible business expansion in this region.

޲Ʊ currently has ten subsidiaries in Europe with the newly established ޲Ʊ Austria. ޲Ʊ will continue to strengthen its business operations in Europe and to address the diversified needs of patients and their families, thereby improving patient value.

[޲Ʊ Austria's Outline]

*You can scroll to the left or right here

Company Name : ޲Ʊ GesmbH
Date of Establishment : April 1, 2009
Capital : 35 thousand euros
Location : Vienna, Austria
General Manager : Georg Wager
Business Operations : Sales and Promotion of Pharmaceutical Products

Contact:

PR Department
޲Ʊ., Ltd.

+81-(0)3-3817-5120